Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 17/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 15/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617154 | 0.94 | MAPKAPK5 (0.44) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL29617156 | 0.94 | MAPKAPK5 (0.44) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461597 | 0.94 | MAPKAPK5 (0.44) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL29617155 | 0.94 | MAPKAPK5 (0.44) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25751396 | 0.87 | MAPKAPK5 (0.42) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25751397 | 0.87 | MAPKAPK5 (0.40) | MAPKAPK5MAPK14MAPK1MAPKAPK2ALOX5AP | |
| SCHEMBL25751341 | 0.85 | MAPKAPK5 (0.47) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25674110 | 0.85 | MAPKAPK5 (0.43) | MAPKAPK5MAPK14MAPK1MAPKAPK2ALOX5AP | |
| SCHEMBL24461779 | 0.85 | MAPKAPK5 (0.43) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25751364 | 0.83 | MAPKAPK5 (0.43) | MAPKAPK5MAPK14MAPK1MAPKAPK2ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | MAPKAPK5 848/4885MAPK14 2275/4885MAPK1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.